EN    EN EN 
SANCO/10402/2007 Rev. 5 (POOL/D1/2007/10402/10402R5-EN.doc)  
EN    EN  COMMISSION OF THE E UROPEAN COMMUNITIES 
Brussels,  
C(2008) final 
Draft 
COMMISSION REGULATION 
of 
amending Annexes VIII, X and XI to Regulation (EC) No 1774/2002 of the European 
Parliament and of the Council as regards the import of blood products for the 
manufacture of technical products 
(Memorandum from Ms A. VASSILIOU)  
EN 2   EN Draft 
COMMISSION REGULATION 
of 
amending Annexes VIII, X and XI to Regulation (EC) No 1774/2002 of the European 
Parliament and of the Council as regards the import of blood products for the 
manufacture of technical products 
(Text with EEA relevance) 
THE COMMISSION OF THE EUROPEAN COMMUNITIES, 
Having regard to the Treaty esta blishing the European Community, 
Having regard to Regulation (EC) No 1774/2002 of the European Parliament and of the 
Council of 3 October 2002 laying  down health rules concer ning animal by-products not 
intended for human consumption1, and in particular Article 4(4), the second paragraph of 
Article 28, the first subparagraph of  Article 29(3) and Article 32(1), 
Whereas: (1) Regulation (EC) No 1774/2002 la ys down animal and public health requirements for 
the import into and transit through the Community of blood products intended for technical purposes, including model import h ealth certificates a nd list of countries 
authorised for imports. 
(2) Regulation (EC) No 1774/2002 provides that  animal by-products which have been 
derived from animals treated with cert ain substances prohibited under Council 
Directive 96/22/EC of 29 April 1996 conc erning the prohibition on the use in 
stockfarming of certain substances having a hormonal or thyrostatic action and of ß-
agonists, and repealing Directives  81/602/EEC, 88/146/EEC and 88/299/EEC
2 may 
only be imported into the Community in accordance with Regulation (EC) 
No 1774/2002 or with specific rules to be laid down. 
                                                 
1 OJ L 273, 10.10.2002, p. 1. Regulation as last amended by Commission Regulation (EC) No 1432/2007 
(OJ L 320, 6.12.2007, p. 13). 
2 OJ L 125, 23.5.1996, p. 3. Directive as amended by Directive 2003/74/EC of the European Parliament 
and of the Council (OJ L 262 14.10.2003, p. 17).  
EN 3   EN (3) The possibility to import such blood produc ts is vital for th e biotechnology industry 
for the manufacture of various technical products used mainly by the pharmaceutical 
and research community. As those products are not intended either for human or 
animal consumption and during their processi ng and technical use they pose no risk to 
animal and human health by reason of being derived from animals treated with certain 
substances prohibited under Di rective 96/22/EC, it is appr opriate to allow the imports 
into the Community of such blood products. 
(4) Regulation (EC) No 1774/ 2002 provides that the blood  products used for the 
manufacture of technical products must be spec ifically treated or the country or region 
of origin of the products must be free fr om certain diseases without vaccination. 
However, several countries or certain regions  are eligible to de liver fresh meat of 
ruminants to the Community by reason of bei ng free from foot and mouth disease with 
vaccination, provided that the risk against possible virus circulation is mitigated. Similarly, it is appropriate to allow imports  of untreated blood products of ruminants 
from such countries or regions, provided that those products ar e channelled to their 
place of destination under secure conditions for further processing. 
(5) Regulation (EC) No 1774/2002 al so provides, in case of blood products of ruminant 
origin that the region of origin must be e ligible for the import of live animals of the 
same species into the Community. According to international standards, blood products are less likely to tran smit diseases of con cern than live animal s. It is therefore 
appropriate to delete this condition from the relevant requirements. 
(6) Part VI(A) of Annex XI to Regulation (EC) No 1774/2002 sets out lists of third 
countries from which Member States may authorise imports of blood products 
intended for technical purposes. Those lists are currently limited to countries from 
which the import of all categories of fresh meat of the respective species for human 
consumption is authorised. 
(7) Since the applicable requirements allow fo r the treatment of the blood products, those 
lists should be extended also to countries wh ich are not authorised to export fresh meat 
of the respective species into the Community but are able to comply with the treatment 
requirements. However, for the sake of clarity, separate health certificates should be laid down for treated and untreated blood products. 
(8) It is appropriate to update the requirements related to  the import of blood products 
from poultry and other avian species by refe rring to the international standards laid 
down in the Terrestrial Animal Health Code  of the World Organisation for Animal 
Health (OIE). 
(9) Annexes VIII, X and XI to Regulation (EC) No 1774/2002 should therefore be 
amended accordingly. 
(10) A transitional period should be provided for af ter the date of entry into force of this 
Regulation, in order to provide the necessary time for the stakeholders to comply with 
the new rules and to allow for the conti nued importation into the Community of the 
blood products as currently cove red by Regulation (EC) No 1774/2002. 
(11) The measures provided for in this Regulati on are in accordance with the opinion of the 
Standing Committee on the Food Chain and Animal Health,  
EN 4   EN HAS ADOPTED THIS REGULATION: 
Article 1 
Annexes VIII, X and XI to Regulation (EC) No 1774/2002 are amended in accordance with 
the Annex to this Regulation. 
Article 2 
Consignments of blood products accompanied by h ealth certificates completed and signed in 
accordance with the provisions of Regulation (E C) No 1774/2002 applicable before the date 
of entry into force of this Regulation shal l be accepted for import into the Community until 
[insert date of 6 months fr om the date of publication ] at the latest. 
Such consignments shall also be accepted until [ insert date of 8 months from the date of 
publication ] at the latest if the accompanying health  certificates were completed and signed 
by [insert date of 6 months from the date of publication ] at the latest. 
Article 3 
This Regulation shall enter into force and apply on the third day following that of its 
publication in the Official Journal of the European Union . 
This Regulation shall be binding in  its entirety and directly applicable in all Member States. 
Done at Brussels, 
 For the Commission 
 Androulla VASSILIOU   Member of the Commission  
EN 5   EN ANNEX  
The Annexes to Regulation (EC) No 1774/2002 are amended as follows: 
(1) In Annex VIII, Chapter IV is replaced by the following: 
"CHAPTER IV 
Requirements for blood and blood produc ts, excluding from equidae, for the 
manufacture of technical products 
A. Importation 
1. Imports of blood are subject to the requirements laid down in Chapter XI. 
2. Member States must authorise import s of blood products for the manufacture 
of technical products, including material  originating from animals to which 
substances prohibited pursuant to Dir ective 96/22/EC have been administered, 
if they: 
(a) come from third countries that appear on the list in Part VI (A) of 
Annex XI as applicable; 
(b) come from a technical plant meetin g the specific conditions laid down in 
this Regulation or from the establishment of collection; 
(c) are accompanied by a health certifi cate that conforms to the model set 
out in Chapter 4(C) or Chapter 4(D) of Annex X as appropriate. 
3. The blood from which blood products for the manufacture of technical 
products are produced must have been collected: 
(a) in slaughterhouses approved in acco rdance with Community legislation; 
(b) in slaughterhouses approved and su pervised by the competent authority 
of the third country; or 
(c) from live animals in facilities approved and supervised by the competent 
authority of the third country. 
4. In the case of blood products for the manufacture of tec hnical products which 
have been derived from animals be longing to the taxa Artiodactyla, 
Perissodactyla and Proboscidea, including th eir crossbreeds, th ey must comply 
with the conditions of either point (a) or (b): 
(a) the products have undergone one  of the following treatments 
guaranteeing the absence of pathogen s of the diseases referred to in 
point (b): 
(i) heat treatment at a temperatur e of 65°C for at least three hours, 
followed by an effectiveness check,  
EN 6   EN (ii) irradiation at 25 kGy by gamm a rays, followed by an effectiveness 
check, 
(iii) heat treatment of at leas t 80 °C throughout their substance, 
followed by an effectiveness check, 
(iv) in the case of animals other than Suidae and Tayassuidae only: 
change in pH to pH 5 for two hours, followed by an effectiveness check; 
(b) in case of blood products not trea ted in accordance with point (a) the 
products originate from a country or region: 
(i) where no case of rinderpest, peste des petits ruminants and Rift 
Valley fever has been recorded for 12 months and in which vaccination has not been carried ou t against those diseases for at 
least 12 months. 
(ii) where no case of foot-and-mout h disease has been recorded for 
12 months and in which vaccination has not been carried out against this disease for at least 12 months 
or 
 where no case of foot-and-mouth disease has been recorded for 
12 months and in which vaccination programmes against foot-and-mouth disease are being officially  carried out and controlled in 
domestic ruminant animals for at least 12 months; in this case, following the border check provided for in Directive 97/78/EC, and 
in accordance with the conditions laid  down in Article 8(4) of that 
Directive, the products must be tran sported directly to the technical 
plant of destination and all precau tions, including safe disposal of 
waste, unused or surplus material, must be taken to avoid risks of 
spreading diseases to animals or humans. 
 In addition to point (i) and (ii), in the case of animals other than Suidae 
and Tayassuidae, one of the following  conditions must be complied with: 
– in the country or region of origin no case of vesicular stomatitis and 
bluetongue (including the presence  of seropositive animals) has 
been recorded for 12 months and vaccination has not been carried 
out against those diseases for at least 12 months in the susceptible species, 
– following the border check provided for in Directive 97/78/EC, and 
in accordance with the conditions laid  down in Article 8(4) of that 
Directive, the products must be tran sported directly to the technical 
plant of destination and all precau tions, including safe disposal of 
waste, unused or surplus material, must be taken to avoid risks of 
spreading diseases to animals or humans.  
EN 7   EN  In addition to point (i) and (ii), in  the case of Suidae and Tayassuidae, in 
the country or region of origin no case of swine vesicular disease, 
classical swine fever and African swin e fever has been recorded for at 
least 12 months, vaccination has not  been carried out against those 
diseases for at least 12 months a nd one of the following conditions are 
complied with: 
– in the country or region of orig in no case of vesicular stomatitis 
(including the presence of seroposit ive animals) has been recorded 
for 12 months and vaccination ha s not been carried out against 
those diseases for at least 12 mont hs in the susceptible species, 
– following the border check provided for in Directive 97/78/EC, and 
in accordance with the conditions laid  down in Article 8(4) of that 
Directive, the products must be tran sported directly to the technical 
plant of destination and all precau tions, including safe disposal of 
waste, unused or surplus material, must be taken to avoid risks of 
spreading diseases to animals or humans. 
5. In the case of blood products for the manufacture of tec hnical products which 
have been derived from poultry and other avian species, they must comply with 
the conditions of either  point (a) or (b): 
(a) the products have undergone one  of the following treatments 
guaranteeing the absence of pathogen s of the diseases referred to in 
point (b): 
(i) heat treatment at a temperatur e of 65°C for at least three hours, 
followed by an effectiveness check, 
(ii) irradiation at 25 kGy by gamm a rays, followed by an effectiveness 
check, 
(iii) heat treatment of at least 70° C throughout their substance, followed 
by an effectiveness check; 
(b) in case of blood products not trea ted in accordance with point (a) the 
products originate from a country or region: 
(i) which has been free from New castle disease and highly pathogenic 
avian influenza as defined in the Te rrestrial Animal Health Code of 
the OIE, 
(ii) which during the last 12 mont hs has not carried out vaccination 
against avian influenza, 
(iii) where the poultry or other av ian species from which the products 
derive have not been vaccinated against Newcastle disease with vaccines prepared from a Newcastl e disease master strain showing 
a higher pathogenicity than lentogenic virus strains."  
EN 8   EN (2) Annex X is amended as follows: 
(a) Chapter 4(C) is replaced by the following: 
'CHAPTER 4(C) 
Health certificate 
For untreated blood products, excluding of equidae, for the manufacture of technical 
products, intended for dispatch  to or for transit through 2 the European Community 
COUNTRY  Veterinary certificate to EU
I.1. Consignor I.2. Certificate reference number 
Name
I.3. Central Competent Authority
Address
I.4. Local Competent Authority
Tel.N°
I.5. Consignee I.6. Person responsible for the consignment in EU 
Name Name
Address Address
Postal code Postal code
Tel.N° Tel.N°
I.7.Country of origin  ISO code I.8. Region of origin Code I.9. Country of destination  ISO code
I.11. Place of origin I.12. Place of destination
Custom warehouse
Name Approval number Name Approval number
Address Address
Postal code
I.13. Place of loading I.14. Date of departure
I.15. Means of transport I.16. Entry BIP in EU 
Aeroplane Ship Railway wagon
Road vehicle Other
Identification:
Documentary references:
I.18. Description of commodity I.19. Commodity code (HS code)
30.02
I.20.Quantity
I.21 Temperature of product I.22. Number of packages
Ambient Chilled Frozen
I.23. Identification of container/Seal number I.24.Type of packaging
I.25. Commodities certified for:
Technical use
I.26. For transit to 3rd Country vis-à-vis EU I.27. For import or admission into EU
3rd country  ISO code
I.28. Identification of the commodities
Approval number of establishments
Species (Scientific name) Nature of commodity Manufacturing plant Batch numberPart I : Details of dispatched consignment I.2.a
I.17.I.10. 
  
EN 9   EN  COUNTRY Untreated blood prod ucts, excluding of equidae,
 for technical products  
 II. Health information II.a. Certificate reference 
number II.b. 
 Part II: Certification 
 
 
 
 II. Health attestation  
I, the undersigned official veterinarian, declar e that I have read and understood Regulation (EC) 
No 1774/2002(1) and in particular Article 4 (1)(c), Article  6 and Chapter IV of Annex VIII thereof and 
certify that the blood products described above:  
II.1. consist of blood products that sa tisfy the health requirements below; 
II.2. consist exclusively of bl ood products not intended for hum an or animal consumption; 
II.3. have been prepared and stored in a plant ap proved, validated and supervised by the competent 
authority in accordance with Article 18 or in the establishment of collecti on and where appropriate 
Article 11 of Regulation (EC) No 1774/2002(2), exclusively with the following animal by-products:  
(2) either [ - blood of slaughtered animals, which is fi t for human consumption in accordance with 
Community legislation, but is not intended fo r human consumption for commercial reasons; ] 
(2) and/or [ - blood of slaughtered animals, which is reject ed as unfit for human consumption but is not 
affected by any signs of diseases communicable to humans or animals, derived from carcasses 
that are fit for human consumption in ac cordance with Community legislation; ] 
(2) and/or [ - blood obtained from animals other than rumina nts that are slaughtered in a slaughterhouse, 
after undergoing ante-mortem inspection, and were fit, as a result of such inspection, for 
slaughter for human consumption in acco rdance with Community legislation; ] 
(2) and/or [ - blood and blood products originating from live an imals that did not show clinical signs of any 
disease communicable through that pr oduct to humans or animals; ] 
II.4. The blood from which such products  are manufactured has been collected: 
(2) either  [ in slaughterhouses approved in accordance with Community legislation, ]  
(2) or [ in slaughterhouses approved and supervised by the competent authority of the third country, ] 
(2) or [ from live animals in facilities approved and supe rvised by the competent authority of the third 
country. ] 
(2) [II.5. in the case of blood products derived from animals  belonging to the taxa Ar tiodactyla, Perissodactyla 
and Proboscidea, including their crossbreds, the products come: 
II.5.1. from a country where no case of rinderpest, peste des petits ruminants and Rift  Valley fever has been 
recorded for 12 months and in which vaccination has not been carried out against those diseases for at 
least 12 months. 
(2) [II.5.2.  either  [ from the territory of a country or region with code …. (3) where no case of foot-and-mouth 
disease has been recorded for 12 months and in which vaccination has not be en carried out against 
those diseases for at  least 12 months ] 
(2) [II.5.2. or [ from the territory of a country or region with code …. (3) where no case of foot-and-mouth 
disease has been recorded for 12 months and in which vaccination programme s against foot-and-mouth 
disease are being officially carried out and controlled in domestic ruminant animals for at least 12 
months(4) ] ] 
(2) [II.5.3.  In addition, in case of animals other than Suidae and Tayassuidae:  
(2) either [ in the country or region of origin no ca se of vesicular stomatitis and bluetongue(2) (including the 
presence of seropositive animals) has been recorded for 12 months and in which vaccination has not 
been carried out against those diseases for at least 12 months, ] 
(2) or [ in the country or region of origin vesicular stomatitis and bluetongue(2) seropositive animals are 
present(4) ] 
(2) [II.5.4.  In addition, in case of Suidae and Tayassuidae: 
[II.5.4.1. [ in the country or region of origin no case of swine vesicular disease, cla ssical swine fever and African 
swine fever has been recorded for at least 12 months  and vaccination has not been carried out against 
those diseases for at least 12 months in the susceptible species ] 
(2) [II.5.4.2. either [ in the country or region of origin no case of vesicular stomatitis (including the presence of 
seropositive animals) has been recorded for 12 months  and in which vaccination has not been carried 
out against those diseases for at least 12 months, ] 
(2) [II.5.4.2. o [ in the country or region of origin vesicu lar stomatitis seropositive animals are present(4) ] ]  
EN 10   EN  COUNTRY Untreated blood prod ucts, excluding of equidae,
 for technical products  
 II. Health information II.a. Certificate reference 
number II.b. 
 
(2) [II.6. in the case of blood products derived from poultry or other avian species the animals and the products 
come from the territory of a country or region with code …. (5)] 
which has been free from Newcastle disease and highl y pathogenic avian influenza as defined in the 
Terrestrial Animal Health Code of the OIE 
which for at least 12 months has not carried out vaccination against avian influenza 
where the animals from which the products derive have  not been vaccinated ag ainst Newcastle disease 
with vaccines prepared from a Newcastle disease ma ster strain showing a higher pathogenicity than 
lentogenic virus strains. ] 
II.7. the product was:  
(2) either  [ packed in new or sterilised bags or bottles, ]  
(2) or [ transported in bulk in containers or other m eans of transport that were thoroughly cleaned and 
disinfected with a disinfectant approved by  the competent authority before use, ] 
 the outer packaging or containers bear labels indicating “NOT FOR HUMAN OR ANIMAL 
CONSUMPTION”; 
II.8. the product was stored in enclosed storage;  
II.9. the product has undergone all precautions to avoi d contamination with pathogenic agents during 
transport. 
 
 
Notes 
Part I: 
y Box reference I.6: Person responsible for the cons ignment in the European Community: this box is to 
be filled in only if it is a certificate for transit comm odity; it may be filled in if the certificate is for 
import commodity. 
y Box reference I.12: Place of destination: this box is to be filled in only if it is a certificate for transit 
commodity. The products in transit can only be st ored in free zones, free warehouses and custom 
warehouses.  
y Box reference I.15: Registration  number (railway wagons or containe r and lorries), flight number 
(aircraft) or name (ship); information is to be  provided in case of unloading and reloading. 
y Box reference I.23: for bulk containers, the cont ainer number and the seal number (if applicable) 
should be included. 
y Box reference I.26 and I.27: fill in  according to whether it is a transit or an import certificate. 
Part II: 
(1) OJ L 273, 10.10.2002, p. 1. 
(2) Delete as appropriate. (3) Code of the territory as it appears in Part 1 of An nex II to Decision 79/542/EEC. 
(4) In this case following the border check provided fo r in Directive 97/78/EC, and in accordance with the 
conditions laid down in Article 8(4) of that Directiv e, the products must be transported directly to the 
technical plant of destination. 
(5) Code of the territory as it appears in Part 1 of An nex II to Decision 2006/696/EC. 
y The signature and the stamp must be in a different colour to that of the printing. 
y Note for the person responsible for the consignmen t in the European Community: this certificate is 
only for veterinary purposes and has to accompany the consignment until it reaches the border inspection post.  
EN 11   EN  COUNTRY Untreated blood prod ucts, excluding of equidae,
 for technical products  
 II. Health information II.a. Certificate reference 
number II.b. 
 Official veterinarian  
 Name (in capital letters): Qualification and title: 
 Date: Signature:  Stamp: 
"  
EN 12   EN (b) The following Chapter 4 (D) is added: 
"CHAPTER 4 (D) 
Health certificate 
For treated blood products, excluding of equidae , for the manufacture of technical products, 
intended for dispatch to or for transit through 2 the European Community 
COUNTRY  Veterinary certificate to EU
I.1. Consignor I.2. Certificate reference number 
Name
I.3. Central Competent Authority
Address
I.4. Local Competent Authority
Tel.N°
I.5. Consignee I.6. Person responsible for the consignment in EU 
Name Name
Address Address
Postal code Postal code
Tel.N° Tel.N°
I.7.Country of origin  ISO code I.8. Region of origin Code I.9. Country of destination  ISO code
I.11. Place of origin I.12. Place of destination
Custom warehouse
Name Approval number Name Approval number
Address Address
Postal code
I.13. Place of loading I.14. Date of departure
I.15. Means of transport I.16. Entry BIP in EU 
Aeroplane Ship Railway wagon
Road vehicle Other
Identification:
Documentary references:
I.18. Description of commodity I.19. Commodity code (HS code)
30.02
I.20.Quantity
I.21 Temperature of product I.22. Number of packages
Ambient Chilled Frozen
I.23. Identification of container/Seal number I.24.Type of packaging
I.25. Commodities certified for:
Technical use
I.26. For transit to 3rd Country vis-à-vis EU I.27. For import or admission into EU
3rd country  ISO code
I.28. Identification of the commodities
Approval number of establishments
Species (Scientific name) Nature of commodity Manufacturing plant Batch numberPart I : Details of dispatched consignment I.2.a
I.17.I.10. 
  
EN 13   EN  COUNTRY Treated blood produc ts, excluding of equidae,
 for technical products  
 II. Health information II.a. Certificate reference 
number II.b. 
 Part II: Certification 
 
 
 
 II. Health attestation  
I, the undersigned official veterinarian, declar e that I have read and understood Regulation (EC) 
No 1774/2002(1) and in particular Article 4 (1)(c), Article  6 and Chapter IV of Annex VIII thereof and 
certify that the blood products described above:  
II.1. consist of blood products that satisfy the requirements below; 
II.2. consist exclusively of bl ood products not intended for hum an or animal consumption; 
II.3. have been prepared and stored in a plant ap proved, validated and supervised by the competent 
authority in accordance with Article 18 or in the establishment of collecti on and where appropriate 
Article 11 of Regulation (EC) No 1774/2002(2), exclusively with the following animal by-products:  
(2) either [ - blood of slaughtered animals, which is fi t for human consumption in accordance with 
Community legislation, but is not intended fo r human consumption for commercial reasons; ] 
(2) and/or [ - blood of slaughtered animals, which is reject ed as unfit for human consumption but is not 
affected by any signs of diseases communicable to humans or animals, derived from carcasses 
that are fit for human consumption in ac cordance with Community legislation; ] 
(2) and/or [ - blood obtained from animals other than rumina nts that are slaughtered in a slaughterhouse, 
after undergoing ante-mortem inspection, and were fit, as a result of such inspection, for 
slaughter for human consumption in acco rdance with Community legislation; ] 
(2) and/or [ - blood and blood products originating from live an imals that did not show clinical signs of any 
disease communicable through that pr oduct to humans or animals. ] 
II.4. The blood from which such products  are manufactured has been collected:  
(2) either  [ in slaughterhouses approved in accordance with Community legislation, ]  
(2) or [ in slaughterhouses approved and supervised by the competent authority of the third country, ] 
(2) or [ from live animals in facilities approved and supe rvised by the competent authority of the third 
country. ]  
(2) [II.5. In case of blood products derived from Artioda ctyla, Perissodactyla and Proboscidea including their 
crossbreeds, other than Suidae and Tayassuidae, the products have undergone one of the following 
treatments, guaranteeing the absence of pathogens of foot-and-mouth disease, vesicular stomatitis, 
rinderpest, peste des petits ruminant s, Rift Valley fever and bluetongue: 
(2) either  [ heat treatment at a temperature of 65°C for at le ast three hours, followed by an effectiveness check, ]  
(2) or [ irradiation at 25 kGy by gamma rays, followed by an effectiveness check, ]  
(2) or [ change in pH to pH 5 for two hour s, followed by an effectiveness check, ]  
(2) or [ heat treatment of at least 80°C throughout their substance, fo llowed by an effectiveness check]]  
(2) [II.6. In the case of blood products derived from Suid ae, Tayassuidae, poultry and other avian species, the 
products have undergone one of the following treatm ents guaranteeing the absenc e of pathogens of the 
following diseases: foot-and-mouth disease, vesicula r stomatitis, swine vesicular disease, classical 
swine fever, African swine fever, Newcastle disease and highly pathogenic avian influenza as 
appropriate to the species; 
(2) either  [ heat treatment at a temperature of 65°C for at le ast three hours, followed by an effectiveness check, ]  
(2) or [ irradiation at 25 kGy by gamma rays, followed by an effectiveness check, ]  
(2) or [ heat treatment of at least 80°C for Suidae/Tayassuidae (2) and at least 70°C for poultry and other avian 
species(2) throughout their substance, follow ed by an effectiveness check ] ]  
(2) [II.7. In the case of blood products derived from specie s other than listed under II.5. or II.6. the products 
have undergone of the following tr eatment (please specify):…………………. ] 
II.8. The product was :  
(2) either  [ packed in new or sterilised bags or bottles, ]  
(2) or [ transported in bulk in containers or other m eans of transport that were thoroughly cleaned and 
disinfected with a disinfectant approved by  the competent authority before use, ] 
the outer packaging or containers bear labels indicating “NOT FOR HUMAN OR ANIMAL 
CONSUMPTION”;   
EN 14   EN  COUNTRY Treated blood produc ts, excluding of equidae,
 for technical products  
 II. Health information II.a. Certificate reference 
number II.b. 
II.9. the product was stored in enclosed storage;  
II.10. the product has undergone all precautions to a void contamination with pathogenic agents after 
treatment. 
 
 
Notes 
Part I: 
y Box reference I.6: Person responsible for the cons ignment in the European Community: this box is to 
be filled in only if it is a certificate for transit comm odity; it may be filled in if the certificate is for 
import commodity. 
y Box reference I.12: Place of destination: this box is to be filled in only if it is a certificate for transit 
commodity. The products in transit can only be st ored in free zones, free warehouses and custom 
warehouses.  
y Box reference I.15: Registration  number (railway wagons or containe r and lorries), flight number 
(aircraft) or name (ship); information is to be  provided in case of unloading and reloading. 
y Box reference I.23: for bulk containers, the cont ainer number and the seal number (if applicable) 
should be included. 
y Box reference I.26 and I.27: fill in  according to whether it is a transit or an import certificate. 
Part II: 
(1) OJ L 273, 10.10.2002, p. 1. 
(2) Delete as appropriate. 
y The signature and the stamp must be in a different colour to that of the printing.  
y Note for the person responsible for the consignmen t in the European Community: this certificate is 
only for veterinary purposes and has to accompany the consignment until it reaches the border 
inspection post.  
 Official veterinarian  
 Name (in capital letters): Qualification and title: 
 Date: Signature: 
 Stamp: 
"  
EN 15   EN (3) In Annex XI, Part VI (A) is replaced by the following: 
"A. Blood products: 
1. Untreated blood products of ungulates:  Third countries or parts of third coun tries listed in Part 1 of Annex II to 
Decision 79/542/EEC from which imports  of fresh meat of any domestic 
ungulate species is authorised and only for the period indicated in column 7 and 8 of that Part, 
Japan 
2. Untreated blood products of pou ltry and other avian species: 
 Third countries or parts of third coun tries listed in Part 1 of Annex II to 
Decision 2006/696/EC 
Japan. 
3. Untreated blood products of other animals:  Third countries listed either in  Part 1 of Annex II to Decision 
79/542/EEC, in Part 1 of Annex II to Commission Decision 2006/696/EC or in Annex I to Commission Decision 2000/585/EC 
Japan. 
4. Treated blood products of any species:  Third countries listed in Part 1 to  Annex II of Decision 79/542/EEC, in 
Part 1 of Annex II to Decision 2006/696/EC or in  Annex I to Decision 
2000/585/EC 
Japan."